
Here are the 3 big things we're watching in the market in the week ahead
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Oil maintains gains ahead of Trump-Putin summit
(Reuters) -Oil prices nudged higher on Friday to fresh one-week highs after U.S. President Donald Trump warned of "consequences" if Russia blocked a Ukraine peace deal, injecting concerns about supply. Sentiment was also boosted by strong economic data out of Japan, which is among the largest global crude importers. Brent crude futures gained 16 cents, or 0.2%, to $67.00 a barrel by (0017 GMT). U.S. West Texas Intermediate crude futures were up 14 cents, also 0.2%, to $64.10. All eyes are on Friday's meeting of Trump and Russian leader Vladimir Putin in Alaska where a ceasefire in the Ukraine war is at the top of the agenda. A continued conflict between Russia and Ukraine supports oil markets by limiting the supply of Russian oil. Trump, however, also said he believes Russia is prepared to end the war in Ukraine. Fresh Japanese government data released on Friday showed the economy expanded an annualised 1.0% in the April-June quarter, compared with a median market forecast for a 0.4% increase. The rise in gross domestic product (GDP) translated into a quarterly increase of 0.3%, compared with a median estimate of a 0.1% increase. Strong economic activity typically spurs oil consumption. Prospects of higher-for-longer U.S. interest rates, however, kept oil prices from rising further. Higher-than-expected inflation data and weak jobs numbers out of the U.S. raised concerns that the Federal Reserve would keep interest rates high, usually a dampener of oil consumption.
Yahoo
25 minutes ago
- Yahoo
24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025
24/7 Market News Issues Corrected Information on Previously issued Press Release with same title DENVER, Aug. 14, 2025 (GLOBE NEWSWIRE) -- a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, spotlights LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage pharmaceutical company focused on developing novel cancer therapies by targeting the modulation of key cellular pathways. 2H 2025 is shaping up to be a defining year for LIXTE. With a focus on its lead compound LB-100, a first-in-class small molecule inhibitor of protein phosphatase 2A (PP2A), a master regulator of cell signaling and DNA damage response. By inhibiting PP2A, LB-100 sensitizes tumors to DNA-damaging agents, including chemotherapy, radiation, and immunotherapy, LIXTE is targeting high-unmet needs in the $200 billion global oncology market (Grand View Research, 2025 projection). Potential upcoming catalysts in 2025, including a first trial result, position LIXTE as a potential disruptor in resistant cancers, where traditional treatments fail due to limited efficacy and toxicity. Upcoming Catalysts: Anticipated Trial Results in 2H 2025 1B/2 Trial – Ovarian Clear Cell Carcinoma (OCCC) Ovarian clear cell carcinoma is an aggressive and chemoresistant subtype of epithelial ovarian cancer, accounting for ~5–10% of all ovarian malignancies but disproportionately contributing to ovarian cancer mortality. The Phase 1B/2 study of LB-100 plus the checkpoint inhibitor dostarlimab (GSK) is designed leverage LB-100's synergistic enhancement of immune checkpoint blockade. Status: Enrolled, with interim safety completed Upcoming Milestone: Preliminary safety and efficacy data expected Q4 2025 Potential Market Impact: Global OCCC treatment market is projected to exceed $750 million by 2028 due to rising incidence and limited targeted therapies 1B/2 Trial – Advanced Soft Tissue Sarcoma (STS) Soft tissue sarcomas are a diverse and difficult-to-treat group of cancers arising from connective tissues. For patients with advanced or metastatic disease, prognosis remains Phase 1B/2 study evaluates LB-100 in combination with doxorubicin, the current standard of care, in patients with advanced STS. Status: Dose escalation completed. Upcoming Milestone: Safety report Q4 2025 Potential Market Impact: The global STS drug market is estimated to reach $2.1 billion by 2030, driven by the emergence of combination therapies and unmet medical need 1B Trial – Metastatic Microsatellite Stable (MSS) Colon Cancer MSS colon cancer, representing roughly 85% of metastatic colorectal cancer (mCRC), remains unresponsive to checkpoint inhibitors. LIXTE is conducting a Phase 1B trial assessing the safety and activity of LB-100 in combination with+ atezolizumab (Roche) (an ICI), seeking to overcome immune resistance in this cold tumor type. Status: Trial open, first patients recruited Potential Market Impact: The global colorectal cancer therapeutics market is expected to surpass $18 billion by 2030, with MSS disease representing the majority of treatment-resistant cases Platform Potential and Market Opportunity LIXTE's strategy of targeting PP2A to potentiate multiple treatment modalities positions LB-100 as a versatile combination agent with broad applicability across solid tumors. The platform's potential spans oncology subtypes with high unmet need, limited innovation, and growing incidence. Strong IP Position: Multiple issued and pending patents covering composition, methods of use, and combinations Pipeline Expansion: Additional tumor types and investigator-sponsored studies are under review, including glioblastoma. Partnership Potential: Ongoing discussions with academic institutions and biopharma partners for co-development opportunities Contact sales@ for Analyst Report coverage and other investor/public relations services. About LIXTE Biotechnology Holdings, Inc. LIXTE is a clinical-stage pharmaceutical company focused on discovering and developing innovative cancer therapies targeting the protein phosphatase 2A (PP2A) pathway, a previously underexplored avenue in cancer treatment. The company's lead compound, LB-100, is a first-in-class PP2A inhibitor that has demonstrated strong preclinical results and early-stage clinical tolerability. LIXTE is currently advancing proof-of-concept trials in Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma. More information can be found at: 24/7 MARKET NEWS, INC DisclaimerPlease go to for further LIXT information and LIXT disclosure information. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law. CONTACT: CONTACT: 24/7 Market News Editor@ in to access your portfolio


CNBC
28 minutes ago
- CNBC
CNBC Daily Open: The Trump administration's mixing business with politics to build a chip empire
Don't mix business with pleasure — or the music of the spheres might eject you from the skies even if you are an astronomer — but it seems, in the current milieu, there are no such restrictions between business and politics. U.S. President Donald Trump's administration is eyeing a stake in struggling chipmaker Intel, according to a Bloomberg report on Thursday. That consideration is primarily attributable to Intel's status as the only born-and-bred American company that can manufacture the fastest chips on U.S. soil. While some firms such as Taiwan Semiconductor Manufacturing Company and Samsung, both of which can produce 3-nanometer chips — the most advanced semiconductors so far — have factories in the U.S., they are Taiwanese and South Korean companies, respectively, and probably do not enjoy apple pies on the Fourth of July. In combination with the news that Nvidia and AMD will pay the U.S. government a 15% share of their revenue from chip sales in China, as well as Apple committing to make more chips in America, the Trump administration seems to be consolidating a chip empire with the White House as its capital. To modify a song last heard by the Astronomer CEO before he was cast down to Earth: "I used to rule the world / Chips would rise when I gave the word."The Trump administration is reportedly considering a stake in Intel. The chipmaker is the only U.S. company that can manufacture the most advanced semiconductors in America. Intel's shares soared 7.4% after Bloomberg reported the news. Wholesale prices in the U.S. heat up. The producer price index for July shot up 0.9% on the month, higher than the Dow Jones estimate of a 0.2% gain. It was the biggest monthly rise since 2022. The annual figure came in at 3.3%, the highest since February. Potential Fed chair David Zervos backs an aggressive rate cut. The Jefferies chief market strategist told CNBC that reaccelerating wholesale prices in July should not deter the central bank from cutting its "restrictive" monetary policy by 50 basis points. U.S. stocks flirt with the flatline. The S&P 500's barest 0.03% gain, however, means it closed at another high on Thursday. The pan-European Stoxx 600 index added 0.55%. Meanwhile, the U.K. economy expanded by a better-than-expected 0.3% in the second quarter. [PRO] European defense stocks will benefit from Trump-Putin meeting. Regardless of whether the talks result in any breakthroughs on the war in Ukraine, analysts think it's a "win-win" situation for defense stocks. Putin vs. Trump? Ukraine talks could be a test of statecraft Russian President Vladimir Putin's standing in the West may be pretty low, but he's a skilled and seasoned statesman who shouldn't be underestimated, analysts say — and he's likely to be looking to outmaneuver his less experienced U.S. counterpart when the leaders meet in Alaska on Friday. "Let's be clear, Putin does not take Trump seriously," Tina Fordham, founder of Fordham Global Foresight, told CNBC ahead of the talks.